Clo­vis' Rubra­ca wins prostate can­cer ap­proval, but da­ta from ri­val Lyn­parza damp­en com­mer­cial ex­pec­ta­tions

While As­traZeneca and Mer­ck’s mar­ket-lead­ing Lyn­parza seem­ing­ly pipped Clo­vis On­col­o­gy’s ri­val Rubra­ca in help­ing prostate can­cer pa­tients, Rubra­ca has, as ex­pect­ed, made it across the fin­ish line first.

On Fri­day, the FDA ap­proved Rubra­ca in pa­tients with BR­CA mu­ta­tion-as­so­ci­at­ed metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) who have been treat­ed pre­vi­ous­ly with an­dro­gen re­cep­tor-di­rect­ed ther­a­py as well as chemother­a­py. The ap­proval marks the first ever for a PARP in­hibitor in the prostate can­cer set­ting.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.